Caxton Associates LP Sells 7,148 Shares of Axonics, Inc. (NASDAQ:AXNX)

Caxton Associates LP decreased its stake in Axonics, Inc. (NASDAQ:AXNX) by 10.8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,159 shares of the company’s stock after selling 7,148 shares during the quarter. Caxton Associates LP’s holdings in Axonics were worth $3,977,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Xponance Inc. raised its position in shares of Axonics by 7.5% in the 2nd quarter. Xponance Inc. now owns 3,231 shares of the company’s stock valued at $217,000 after acquiring an additional 225 shares during the period. Headlands Technologies LLC raised its position in shares of Axonics by 31.1% during the first quarter. Headlands Technologies LLC now owns 1,117 shares of the company’s stock worth $77,000 after purchasing an additional 265 shares during the period. Arizona State Retirement System lifted its holdings in shares of Axonics by 2.5% during the 2nd quarter. Arizona State Retirement System now owns 14,278 shares of the company’s stock valued at $960,000 after purchasing an additional 355 shares in the last quarter. Scholtz & Company LLC grew its position in shares of Axonics by 7.8% in the 4th quarter. Scholtz & Company LLC now owns 4,985 shares of the company’s stock valued at $310,000 after purchasing an additional 360 shares during the period. Finally, Whittier Trust Co. increased its stake in Axonics by 59.1% during the 1st quarter. Whittier Trust Co. now owns 1,142 shares of the company’s stock worth $79,000 after purchasing an additional 424 shares in the last quarter. Institutional investors own 99.48% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Monday, August 5th. Eight research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Axonics presently has a consensus rating of “Hold” and a consensus price target of $69.57.

Axonics Stock Performance

NASDAQ AXNX opened at $69.26 on Wednesday. Axonics, Inc. has a 52 week low of $48.30 and a 52 week high of $69.68. The stock’s 50 day moving average price is $68.72 and its two-hundred day moving average price is $67.97.

Axonics (NASDAQ:AXNX) last announced its quarterly earnings data on Thursday, August 1st. The company reported $0.13 EPS for the quarter, topping analysts’ consensus estimates of $0.10 by $0.03. The business had revenue of $114.57 million for the quarter, compared to analyst estimates of $112.83 million. Axonics had a negative net margin of 0.42% and a negative return on equity of 0.27%. The firm’s revenue for the quarter was up 23.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.15) earnings per share. Analysts anticipate that Axonics, Inc. will post 0.24 earnings per share for the current year.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.